p53 and stem cells: new developments and new concerns
- PMID: 20061153
- DOI: 10.1016/j.tcb.2009.12.004
p53 and stem cells: new developments and new concerns
Abstract
As the guardian of the genome, the tumor suppressor p53 prevents the accumulation of genetic mutations by inducing cell cycle arrest, apoptosis or senescence of somatic cells after genotoxic and oncogenic stresses. Recent studies have identified the roles of p53 in suppressing pluripotency and cellular dedifferentiation. In this context, p53 suppresses the self-renewal of embryonic stem cells after DNA damage and blocks the reprogramming of somatic cells into induced pluripotent stem cells (iPSCs). If the inactivation of p53 pathway is a prerequisite for successful reprogramming, these findings raise concerns for the genomic stability and tumorigenecity of iPSCs and their derivatives. Elucidation of the roles of p53 as a barrier to pluripotency and cellular dedifferentiation might also reveal the mechanisms by which p53 coordinates tumor suppression and aging.
Similar articles
-
The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells.Stem Cells. 2010 Apr;28(4):721-33. doi: 10.1002/stem.404. Stem Cells. 2010. PMID: 20201066
-
Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation.Cancer Res. 2012 Nov 1;72(21):5635-45. doi: 10.1158/0008-5472.CAN-12-1451. Epub 2012 Sep 10. Cancer Res. 2012. PMID: 22964580
-
The emerging role of p53 in stem cells.Trends Mol Med. 2012 Jan;18(1):6-12. doi: 10.1016/j.molmed.2011.08.002. Epub 2011 Sep 7. Trends Mol Med. 2012. PMID: 21907001
-
Generation and genetic modification of induced pluripotent stem cells.Expert Opin Biol Ther. 2010 Jul;10(7):1089-103. doi: 10.1517/14712598.2010.496775. Expert Opin Biol Ther. 2010. PMID: 20528610 Review.
-
[Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].Rev Invest Clin. 2001 May-Jun;53(3):266-73. Rev Invest Clin. 2001. PMID: 11496714 Review. Spanish.
Cited by
-
Evolutionary determinants of curability in cancer.Nat Ecol Evol. 2023 Nov;7(11):1761-1770. doi: 10.1038/s41559-023-02159-w. Epub 2023 Aug 24. Nat Ecol Evol. 2023. PMID: 37620552 Review.
-
Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.Am J Pathol. 2011 Jul;179(1):422-35. doi: 10.1016/j.ajpath.2011.03.035. Epub 2011 May 13. Am J Pathol. 2011. PMID: 21703421 Free PMC article.
-
Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.Cell Cycle. 2014;13(3):358-70. doi: 10.4161/cc.27770. Epub 2014 Jan 9. Cell Cycle. 2014. PMID: 24406535 Free PMC article.
-
Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency.Cell Regen. 2015 Nov 11;4:10. doi: 10.1186/s13619-015-0024-9. eCollection 2015. Cell Regen. 2015. PMID: 26566431 Free PMC article.
-
Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.Stem Cells. 2010 Dec;28(12):2129-40. doi: 10.1002/stem.538. Stem Cells. 2010. PMID: 20936707 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous